Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWRBiotechnology
+$4.49 today
- Market cap
- $6.09B
- Beta
- 1.27
- P/E (TTM)
- -38.4
- EPS (TTM)
- -$2.11
Volume 2.42M
Average 1.82M
ARWR Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR
Cash & Equivalents · Q4 FY2026 · quarter ended Sep 2026
Cash & equivalents falls 72.3% from a year ago
Cash & equivalents stood at $62.74M at the end of Q4 FY2026, down 72.3% from a year earlier and up 14.6% from the prior quarter. Over 3 fiscal years it compounded at -17.3% a year.
Context
- Cash & equivalents amounted to 3.6% of total assets at the end of Q4 FY2026, down 12.7 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -72.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2026
- 62.74M USD
- Year-over-year change
- -72.3%
- 4-year CAGR
- -12.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | 62.74M | -72.3% |
| FY2025 | 2025-09-30 | 226.55M | +120.6% |
| FY2024 | 2024-09-30 | 102.69M | -7.4% |
| FY2023 | 2023-09-30 | 110.89M | +2.7% |
| FY2022 | 2022-09-30 | 108.01M | — |
Cash & Equivalents vs competitors
How ARWR compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -72.3% is the 6th highest of 7, against a peer median of -7.5%.
- Cash & equivalents amounts to 3.6% of total assets for ARWR, versus a peer median of 56.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.71B USD | +53.4% | +24.1% | 30.7% | |
| Mar 2026 | $544.59M USD | +124.0% | +89.5% | 93.3% | |
| Sep 2026 | $296.3M USD | -12.4% | +10.4% | 10.2% | |
| Mar 2026 | $211.38M USD | -2.6% | -16.2% | 86.1% | |
| Mar 2026 | €81.17M EUR | -43.2% | -0.9% | 81.9% | |
| Sep 2026 | $62.74M USD | -72.3% | -17.3% | 3.6% | |
| Mar 2026 | $5.66M USD | -91.3% | -41.0% | 4.9% | |
| Peer median (excluding ARWR) | — | -7.5% | +4.8% | 56.3% | |
Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 108.01M | 110.89M | 102.69M | 226.55M | 62.74M |
| Short-term Investments | 268.39M | 292.74M | 578.28M | 692.82M | 1.13B |
| Net Receivables | 1.41M | 0 | 0 | 6.82M | 9.93M |
| Inventory | (21.61M) | 0 | 0 | 0 | 9.08M |
| Other Current Assets | 41.82M | 7.08M | 4.97M | 13.52M | 45.65M |
| Total Current Assets | 405.3M | 419.52M | 695.47M | 950.64M | 1.29B |
| Property, Plant & Equipment (Net) | 168.59M | 335.56M | 431.29M | 426.41M | 429.65M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 11.96M | 10.26M | 8.56M | 6.86M | 5.16M |
| Long-term Investments | 105.87M | 0 | 0 | 0 | 7.5M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 218K | 210K | 4.48M | 1.39M | 6.73M |
| Total Non-current Assets | 286.64M | 346.03M | 444.33M | 434.66M | 449.04M |
| Total Assets | 691.94M | 765.55M | 1.14B | 1.39B | 1.74B |
| Account Payables | 2.87M | 35.87M | 11.39M | 17.67M | 30.15M |
| Short-term Debt | 2.78M | 10.56M | 6.34M | 40M | 40M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 74.1M | 866K | 0 | 2.4M | 91.65M |
| Other Current Liabilities | 46.86M | 40.2M | 63.45M | 80.43M | 7.01M |
| Total Current Liabilities | 138.85M | 105.46M | 103.17M | 195.49M | 311.34M |
| Long-term Debt | 0 | 268.33M | 734.54M | 214.88M | 838.88M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 55.95M | 0 | 0 | 0 | 21.34M |
| Other Non-current Liabilities | 0 | 0 | 0 | 367.4M | 400.38M |
| Total Non-current Liabilities | 134.75M | 372.93M | 845.57M | 686.39M | 1.38B |
| Total Liabilities | 273.6M | 478.39M | 948.74M | 881.88M | 1.69B |
| Common Stock | 198K | 200K | 217K | 231K | 237K |
| Retained Earnings | (820.76M) | (1.03B) | (1.63B) | (1.63B) | (2.35B) |
| Accumulated OCI | (136K) | (3.22M) | 4.75M | 6.44M | (7.65M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 19.82M | 15.82M | 5.62M | 37.36M | 191K |
| Total Equity | 418.34M | 287.16M | 191.06M | 503.42M | 50.5M |
| Total Debt | 81.58M | 383.5M | 851.91M | 366.28M | 1B |
| Net Debt | (26.43M) | 272.61M | 749.23M | 139.74M | 937.46M |
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
Intrinsic Alpha fair value
Locked
Current Price
$43.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.